Effect of inhibit or AMD3100 of CXCR4 on liver metastasis of colorectal cancer

Chun-kang YANG,Chen-xing JIAN,Min-gang YING
DOI: https://doi.org/10.16073/j.cnki.cjcpt.2010.18.017
2010-01-01
Abstract:OBJECTIVE, To investigate the inhibition of the specific CXCR4 antagonist AMD3100 in colorectal carcinoma liver metastasis and explore its control mechanism in vivo. METHODS: A mouse model of colorectal cancer liver metastasis was established by splenectomy technique. The 18 nude mice were randomly divided into 3 groups, a control group (0.1 mL saline solution), treatment group of low dose AMD3100 (4 mg/kg ) and treatment group of high dose AMD3100(6 mg/kg) . Six weeks after implantation,the differences of liver metastasis among the groups were compared. RESULTS: The diameters of the spleen primary tumors were (13. 83±7. 73) mm(the control group),(5. 17±0.75) mm(the treatment group of low dose AMD3100)and (2.83±1.33) mm (the treatment group of high dose AMD3100) respectively (P<0. 05); and the diameters of the liver metastasis were (3.42±2. 24) mm,(2.26±1.12) mm and (1.62±0.88) mm respectively (P<0.05); numbers of the liver metastasis were 21.00±3. 90, 13.00±1.79 and 2.17±1.37 respectively (P< 0.05). CONCLUSIONS: The specific CXCR4 antagonist AMD3100 greatly affects the development of liver metastasis in colorectal cancer. It can inhibit the growth of the liver metastasis tumor in colorectal carcinoma and it is more effective of the high dose than of the low dose in the experiment.
What problem does this paper attempt to address?